Basel-based SunRegen Healthcare AG has entered into a binding Letter of Intent dated August 12, 2024 with Verisante Technology Inc, a company listed on the Canadian TSX Venture Exchange, to undertake a Reverse Takeover transaction with the resulting listed issuer carrying on the business of SunRegen. SunRegen focusses on the development of neurodegenerative related drugs.
